Choose a country below to begin
- EU-M4all (formerly Article 58) - Standard Procedure
- PRIME (PRIority MEdicines)
- EMA Accelerated Assessment
- EMA Adaptive Pathways
- EMA Advanced Therapy Medicinal Products
- EMA Marketing Authorisation under Exceptional Circumstances
- EMA Conditional Marketing Authorisation
- Opening procedures at EMA to non-EU authorities (OPEN) initiative
- EMA initiatives for acceleration of development support and evaluation procedures for COVID-19 treatments and vaccines
- EU-M4all (formerly Article 58) - Accelerated Assessment
- EU-M4all (formerly Article 58) - Conditional Article 58 scientific opinion
- EU-M4all (formerly Article 58) - Article 58 scientific opinion under exceptional circumstances
- FDA-EMA Parallel Scientific Advice Pilot Program for Complex Generic/Hybrid Products
- PRIME (PRIority MEdicines)
- EMA Accelerated Assessment
- EMA Adaptive Pathways
- EMA Advanced Therapy Medicinal Products
- EMA Marketing Authorisation under Exceptional Circumstances
- EMA Conditional Marketing Authorisation
- Opening procedures at EMA to non-EU authorities (OPEN) initiative
- EMA initiatives for acceleration of development support and evaluation procedures for COVID-19 treatments and vaccines
- EU-M4all (formerly Article 58) - Accelerated Assessment
- EU-M4all (formerly Article 58) - Conditional Article 58 scientific opinion
- EU-M4all (formerly Article 58) - Article 58 scientific opinion under exceptional circumstances
- FDA-EMA Parallel Scientific Advice Pilot Program for Complex Generic/Hybrid Products
- Swissmedic Article 13 Therapeutic Product Act (TPA)
- Swissmedic Marketing Authorisation for Global Health Products (MAGHP) Procedure
- Procedure with prior notification (PPN)
- Fast-track authorisation procedure (FTP)
- Temporary authorisation for human medicinal products
- Simplified Authorization Procedure (Art. 14)
- Marketing Authorisation for Global Health Products (MAGHP) Light Procedure
- Swissmedic Marketing Authorisation for Global Health Products (MAGHP) Procedure
- Procedure with prior notification (PPN)
- Fast-track authorisation procedure (FTP)
- Temporary authorisation for human medicinal products
- Simplified Authorization Procedure (Art. 14)
- Marketing Authorisation for Global Health Products (MAGHP) Light Procedure
- Innovative Licensing and Access Pathway (ILAP)
- European Commission Decision Reliance Procedure (ECDRP)
- Decentralised and mutual recognition reliance procedure for marketing authorisations (MRDCRP)
- Conditional Marketing Authorisation Applications (CMA)
- Great Britain Marketing Authorisations under exceptional circumstances
- 150-day assessment for national applications for medicines
- Orphan medicinal products
- Early Access to Medicines Scheme (EAMS)
- Unfettered Access Procedure (UAP)
- International Recognition Procedure - Recognition A
- International Recognition Procedure - Recognition B
- European Commission Decision Reliance Procedure (ECDRP)
- Decentralised and mutual recognition reliance procedure for marketing authorisations (MRDCRP)
- Conditional Marketing Authorisation Applications (CMA)
- Great Britain Marketing Authorisations under exceptional circumstances
- 150-day assessment for national applications for medicines
- Orphan medicinal products
- Early Access to Medicines Scheme (EAMS)
- Unfettered Access Procedure (UAP)
- International Recognition Procedure - Recognition A
- International Recognition Procedure - Recognition B